|Bid||79.72 x 900|
|Ask||79.94 x 900|
|Day's Range||79.39 - 80.60|
|52 Week Range||39.07 - 81.03|
|Beta (3Y Monthly)||1.98|
|PE Ratio (TTM)||38.61|
|Earnings Date||May 2, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||65.46|
Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS) today announced that data from the NEURO-TTR open-label extension study and the clinical impact of TEGSEDI on patients living with hereditary transthyretin amyloidosis (hATTR) will be presented at the American College of Cardiology’s 68th Annual Scientific Session (ACC) in New Orleans, March 16-18, 2019.
Ionis is the IBD Stock Of The Day as shares form a short stroke after the biotech obliterated quarterly earnings estimates. Ionis turned around a profit, though analysts expected losses.
The most expensive stocks often receive a disproportionate share of the coverage in the financial news industry. Since those stocks often emerge from cutting-edge industries, they tend to win investor attention as they often represent the future.Assuming the company earns a profit, they usually get classified as the most expensive stock through their price-to-earnings (P/E) ratio. The average P/E ratio for an S&P 500 company comes in at about 21.4. However, these stocks command much higher P/E ratios, often into the triple digits. Due to their usually phenomenal growth, these stocks can maintain triple-digit multiples for years. * 10 Tech Stocks to Buy Now for 2025 However, high growth rarely lasts forever. While slowing growth rarely makes these equities cheap stocks, it becomes a time when many of the most expensive stocks go on sale. These six equities, which have often become the most expensive stocks in the recent past, appear poised to trade at sale prices:InvestorPlace - Stock Market News, Stock Advice & Trading TipsSource: Shutterstock Chipotle (CMG)Fast-food stocks rarely make it on a list of most expensive stocks, but the success of the healthy fast food trend Chipotle (NYSE:CMG) pioneered has taken that equity to record highs. Not even outbreaks of E. coli or other cases of food poisoning have not permanently derailed its move higher.Today, CMG stock trades at a P/E of 98. Profit growth takes the forward P/E to just under 40. However, I think Chipotle's days of trading at an elevated multiple may end soon. Other fast-food eateries have latched on to the healthy food trend. Restaurants such as Zoe's Kitchen, Modern Market and many others have emerged. Moreover, established brands such as McDonald's (NYSE:MCD) now offer healthier options.Most remain private for now, but as more of these firms launch IPO's, investors will have several healthy fast-food restaurants from which to choose. Wall Street expects Chipotle to increase profits by an average of 24% per year for the next five years. For this reason, I expect a more gradual drop in the P/E ratio. However, over time I think CMG stock will eventually fall to a P/E ratio comparable to that of McDonald's. Since that trend has already begun, I would recommend avoiding CMG stock at these levels.Source: Shutterstock GoDaddy (GDDY)The public may know GoDaddy (NYSE:GDDY) best for Super Bowl commercials. However, it earns revenue as a domain registrar and web hosting service. Despite its thin-moat business, it has managed to acquire 18 million customers and hold 77 million domain names under management. This strategy has helped GDDY stock grow to a P/E ratio of 164 and will bring a 73.3% profit increase this year if Wall Street's forecasts come to fruition.However, I think the weak moat makes profit forecasts untrustworthy. The problem for GDDY is that consumers who want to register a domain or find web hosting have numerous companies from which to choose. Hence, the Super Bowl commercials and the GoDaddy name constitute its entire moat. Moreover, Danica Patrick's retirement from racing has reduced the exposure she brought to the company. If people start to remember that other hosting companies exist, it could lead to a lower market share and reduced profit growth. * 10 Top Pot Stocks 2019 Has to Offer Despite the problems, I think highly of GoDaddy as a company. Achieving this level of earnings growth in a business with almost no moat stands as an impressive feat. However, I think that weak moat means GDDY stock will not stay on the most expensive stocks list for much longer.Source: Shutterstock Ionis Pharmaceuticals (IONS)Ionis (NASDAQ:IONS) specializes in antisense technology. This allows for the manipulation of genes to treat diseases. The company is best known for the drug Spinraza, a therapy which it developed with Biogen (NASDAQ:BIIB) for spinal muscular atrophy. Ionis also leads the way in RNA therapies.Where it cannot seem to lead the way is in stock price growth. IONS stock trades at around $70 per share. This takes it to a record high, but it also means it could form a double-top as it slightly exceeds the record levels in 2015. Moreover, the spike in profits in 2018 occurred from a one-time, $292 million tax event in the fourth quarter. Without such events, the forward P/E ratio rises to just above 201.Analysts predict an average profit growth rate of 40% per year for the next five years. However, with drops in earnings coming for both this year and next, one has to wonder whether that forecast will hold. Even if IONS stock makes or exceeds that profit growth, whether it justifies its high multiple remains in question. While I expect Ionis to develop innovative therapies, measuring how much they succeed remains difficult. Between the possible double top in the charts, a 201 forward P/E and an uncertain future, I find it difficult to stay optimistic about the near-term prospects of IONS stock.Source: Vivian D Nguyen via Flickr (Modified) Netflix (NFLX)As the pioneer in streaming video, Netflix (NASDAQ:NFLX) stock has remained a growth powerhouse for many years. Triple-digit P/E ratios and threats from competing streaming services have failed to stop the growth in NFLX stock. Over the last few years, Netflix has maintained this growth by developing award-winning, popular content and partnering with the likes of Disney (NYSE:DIS) to offer a wide variety of viewing choices.However, Disney now plans to offer its own streaming service. With that, much of its popular content switches from a company asset to a competitive threat. Moreover, the high costs of in-house content development have increased the debt load on Netflix's balance sheet. Netflix has increased fees to mitigate that cost. However, with Disney charging only $4.95 for its ESPN+ streaming services, they could choose to undercut Netflix and diminish the company's ability to increase fees. * 7 Top Stocks to Buy From Goldman Sachs' Secret Portfolio Granted, streaming services are a bargain compared to the traditional pay TV services. For this reason, rising prices may not lead to revenue declines. Still, in a world with many peers, maintaining the high multiple of NFLX stock could become difficult. Moreover, the forward P/E ratio, which now stands at just under 55, has fallen in recent years. This could trigger further stock dilution as Netflix needs options to pay down its debt. I expect Netflix to remain a content powerhouse for years to come, but with rising debts and increased competition, NFLX will probably not stay on the list of most expensive stocks.Source: Shopify via Flickr Shopify (SHOP)I have often referred to Shopify (NYSE:SHOP) stock as the "anti-Amazon," the company that allows one to set up shop without the help of online giant Amazon (NASDAQ:AMZN). Shopify's platform allows any entrepreneur to build and operate an online store with minimal development skills. Given that reality, one can see why it earned its place on many most expensive stocks lists.Since it trades at over 18 times sales and almost ten times book value, most would call SHOP stock pricey. Moreover, factors have emerged that would call these multiples as well as its 216.9 forward P/E ratio into question. Competitors such as WooCommerce and Magento, a product owned by Adobe (NASDAQ:ADBE) offer credible alternative platforms to online entrepreneurs. Amazon and Square (NYSE:SQ) have also targeted its customer base.Wall Street expects average earnings increases of 56.3% per year over the next five years. Also, all e-commerce platform developers should benefit from the massive growth the industry will enjoy for the foreseeable future. However, Shopify has yet to turn an annual profit. With all of the available alternatives, more investors will probably question the current valuation of SHOP stock.Source: Web Summit Via Flickr Twilio (TWLO)Twilio (NYSE:TWLO) has earned its designation among the most expensive stocks with its forward P/E ratio of almost 430. TWLO dominates the platform-as-a-service (PaaS) for cloud-based APIs. In layman's terms, this is the technology that enables firms such as Uber to operate their services.Although analysts foresee profits falling this year, they believe earnings will grow by an average 36.5% per year over the next five years. I think this rate of increase deserves a higher-than-average multiple. However, this growth rate still cannot possibly justify a 430 forward P/E multiple.Moreover, competition has become an increasing threat as smaller competitors have emerged. TWLO stock fell recently when news came out that Uber was looking to reduce its dependence on Twilio. The stock could also drop precipitously if companies such as Amazon (who serves as Twilio's hosting company) or Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL) decide to enter this market. * 7 Dividend Stocks Already Rewarding Shareholders In 2019 No matter the size of Twilio's direct peers, competition will pose an increasing threat. I expect this industry to see massive growth over the next few years. However, even exponential growth has its limits. With its 400-plus forward P/E and new competitors emerging, I think TWLO stock has nowhere to go but down.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dividend Stocks Already Rewarding Shareholders In 2019 * The 10 Best-Performing ETFs This Year * 7 Stocks That Should Be Worried About a Data Dividend Compare Brokers The post 6 of the Most Expensive Stocks That Could Go On Sale appeared first on InvestorPlace.
As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.
Ionis Pharmaceuticals Inc NASDAQ/NGS:IONSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for IONS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding IONS are favorable, with net inflows of $3.01 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Ionis Pharmaceuticals Inc is the RNA-targeted drug discovery and development company. Warning! GuruFocus has detected 2 Warning Sign with CNS. For the last quarter Ionis Pharmaceuticals Inc reported a revenue of $192.1 million, compared with the revenue of $161.3 million during the same period a year ago.
An advisory committee of the European Medicines Agency (EMA) on Friday recommended conditionally approving a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals Inc that aims to treat a rare genetic disease that causes fat accumulation in the blood. The nod from EMA's Committee for Medicinal Products for Human Use is a shot in the arm for the companies after their shares plunged in August when the U.S. Food and Drug Administration declined to approve the drug, Waylivra. Waylivra is designed to treat familial chylomicronemia syndrome, a rare genetic disorder that can cause a potential fatal inflammation of the pancreas.
Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending conditional marketing authorization for WAYLIVRA as an adjunct to diet in adult patients with genetically confirmed familial chylomicronemia syndrome (FCS) who are at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate. Click here to read the EMA’s press release. The positive opinion will now be referred to the European Commission (EC), which grants marketing authorization for medicines in the European Union for the adoption of a decision on an EU-wide marketing authorization.
Total revenue increased 17% compared to 2017 to $600 million Commercial revenues more than doubled Conference call and webcast today, February 27, 2019, at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Feb. ...
Novartis will pay $150 million to Ionis Pharmaceuticals to license an RNA-targeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto. Novartis will do a Phase 3 trial of TQJ230, also known as AKCEA-APO(a)-LRx, against an inherited form of cardiovascular disease where people have elevated levels of so-called lipoprotein (a) that cannot effectively be cut via diet and lifestyle changes and plays a role in the narrowing of the arteries, heart attacks, thrombosis and stroke.
Novartis (NVS) in-licenses rights to develop and commercialize TQJ230 from Ionis Pharmaceuticals for treating targeted cardiovascular diseases.
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CARLSBAD, Calif., Feb. 13, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) announced today that it will host a live webcast on Wednesday, February 27th at 11:30 a.m. Eastern Time to discuss its 2018 financial results and report on pipeline and business progress. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, proprietary antisense technology platform with the potential to treat diseases where no other therapeutic approaches have proven effective.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Stan Crooke became the CEO of IonisRead More...
Ionis Pharmaceuticals Inc (NASDAQ: IONS )'s partner Biogen Inc (NASDAQ: BIIB ) reported fourth-quarter results Wednesday before the market open, revealing that sales of the spinal muscular atrophy treatment ...